About: Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 21 September 2015

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2015 (ast) наукова стаття, опублікована у вересні 2015 (uk) scientific article published on 21 September 2015 (en) مقالة علمية نشرت في 21 سبتمبر 2015 (ar)
publication date	wds:Q37166431-051F83E3-1685-4D3C-8037-87B276A243FF
publication date	2015-09-21 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37166431-3DF03CC2-DB4C-4785-939E-D29AD8837C56
language of work or name	English
cites work	wds:Q37166431-0559F76C-0C37-440C-8FC7-E12DD36A264C wds:Q37166431-06A18BA5-A2AC-47DD-B5AA-0C4BB8CFDC54 wds:Q37166431-30943800-7ABA-4FE3-90B0-3E05EBF799F8 wds:Q37166431-3197FF7E-A055-49D4-AE6D-8D9837C410DA wds:Q37166431-328562C9-0C82-48A4-B72F-721709A38DA0 wds:Q37166431-36C6732B-782B-45D4-BB78-B5993EFB173A wds:Q37166431-51586E89-6917-48B6-845B-34976307E224 wds:Q37166431-5BDF8169-4758-4028-A6F4-E9609162851C wds:Q37166431-63D1D381-857B-4B75-A9EC-08C7A62D3999 wds:Q37166431-76AF3C5B-CFAD-4F30-8C42-D126C080AC1A wds:Q37166431-82A50681-B25C-45CC-832B-782882C6557B wds:Q37166431-AE64E007-68F4-4B68-99B5-2F0FE82D2295 wds:Q37166431-B51C2089-26AF-4188-B566-D7CE98B5FC0D wds:Q37166431-C13CB8B7-E920-4880-9B4C-67712C89100B wds:Q37166431-C5E6BBAE-51AD-4A26-87EA-46F9C6DC2EC0 wds:Q37166431-D0DD6087-5543-478D-BDCA-84BBF63BBA5C wds:Q37166431-D6B9EE1A-7553-4461-90DB-6866F9A3FA81
cites work	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity Trastuzumab containing regimens for early breast cancer Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Adjuvant trastuzumab in HER2-positive breast cancer Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer Trastuzumab-related cardiotoxicity among older patients with breast cancer
author name string	wds:Q37166431-3ED096A6-2B80-4BCB-8A5A-BAB64B0B5D27 wds:Q37166431-696E91BA-95FA-4539-9512-8D93398BF430 wds:Q37166431-6E4AC1D7-78AE-4570-8486-3A3BDEE468C5 wds:Q37166431-EE9D1086-64DA-4D05-B7B9-11E6A10B4167
author name string	Karla V Ballman Gerardo Colon-Otero Pooja P Advani Travis J Dockter
rdfs:label	Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (en) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (ast) Long-Term Cardiac Safety Analysis of NCCTG N9831 (nl)
skos:prefLabel	Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (en) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (ast) Long-Term Cardiac Safety Analysis of NCCTG N9831 (nl)
name	Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (en) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (ast) Long-Term Cardiac Safety Analysis of NCCTG N9831 (nl)
author	wds:Q37166431-DDB9766E-227A-4F09-9F4C-95DA1783A2C4
author	Edith A. Perez
title	wds:Q37166431-9661CE5F-2A1A-44F9-A3B7-FF4BA7481484
title	Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial (en)
page(s)	wds:Q37166431-2FED0F95-9F72-42C6-ADBA-6B960B56FDE3
page(s)	581-587
instance of	wds:Q37166431-856E5F8C-D903-4888-99CD-310C13F02DF8
instance of	scholarly article
main subject	wds:Q37166431-342862C4-788B-4530-87DF-2BFDC0443B34
main subject	trastuzumab
PubMed ID	wds:Q37166431-28F5F496-1FA0-4BB5-A063-961CCCCB7416
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26392097
PubMed ID	26392097
published in	wds:Q37166431-2A5AE799-742F-4F2A-A303-91AA172BAEE7
published in	Journal of Clinical Oncology
issue	wds:Q37166431-03049A4D-3C66-4216-89B3-29256F2EBCBF
volume	wds:Q37166431-8EED8FBF-E707-467E-AE48-14EB963097C6
issue	6
volume	34
DOI	wds:Q37166431-7BDCC119-DA93-4C4A-BDBF-1ED6DA4CFF35
DOI	http://dx.doi.org/10.1200/JCO.2015.61.8413
DOI	10.1200/JCO.2015.61.8413
PMCID	wds:Q37166431-32536FF5-1823-4233-B37F-3B95584FD8B3
PMCID	4980566
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37166431
is cites work of	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter Twenty years of anti-HER2 therapy-associated cardiotoxicity

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software